The Institute for Clinical and Economic Review (ICER) evaluated MDMA-AP for PTSD. This report presents the summary of our systematic literature review and cost-effectiveness analysis and highlights the key policy recommendations discussed at the New England Comparative Effectiveness Public Advisory Council’s public meeting on May 30, 2024. The ICER Final Evidence Report on MDMA-AP for PTSD is available at: icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf
